Illinois Municipal Retirement Fund Has $16.51 Million Position in Boston Scientific Co. (NYSE:BSX)

Illinois Municipal Retirement Fund grew its position in Boston Scientific Co. (NYSE:BSX) by 13.9% during the 4th quarter, Holdings Channel reports. The firm owned 184,802 shares of the medical equipment provider’s stock after purchasing an additional 22,504 shares during the quarter. Illinois Municipal Retirement Fund’s holdings in Boston Scientific were worth $16,507,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. Private Advisor Group LLC boosted its position in Boston Scientific by 2.7% in the third quarter. Private Advisor Group LLC now owns 36,003 shares of the medical equipment provider’s stock valued at $3,017,000 after buying an additional 944 shares in the last quarter. PFG Investments LLC increased its holdings in shares of Boston Scientific by 3.3% during the third quarter. PFG Investments LLC now owns 7,988 shares of the medical equipment provider’s stock worth $669,000 after buying an additional 258 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its stake in shares of Boston Scientific by 123.1% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 158,538 shares of the medical equipment provider’s stock valued at $13,285,000 after acquiring an additional 87,470 shares during the last quarter. Cavalier Investments LLC boosted its holdings in shares of Boston Scientific by 6.7% in the 3rd quarter. Cavalier Investments LLC now owns 71,841 shares of the medical equipment provider’s stock worth $6,020,000 after acquiring an additional 4,485 shares in the last quarter. Finally, Patriot Financial Group Insurance Agency LLC grew its position in Boston Scientific by 11.8% during the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 13,718 shares of the medical equipment provider’s stock worth $1,150,000 after acquiring an additional 1,445 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Down 0.2 %

NYSE:BSX opened at $104.30 on Tuesday. Boston Scientific Co. has a 1 year low of $65.52 and a 1 year high of $107.17. The stock has a 50-day moving average price of $98.25 and a two-hundred day moving average price of $89.69. The stock has a market cap of $153.92 billion, a price-to-earnings ratio of 83.44, a PEG ratio of 2.79 and a beta of 0.80. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. As a group, equities analysts expect that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Insider Buying and Selling

In other Boston Scientific news, EVP John Bradley Sorenson sold 1,201 shares of Boston Scientific stock in a transaction on Friday, February 14th. The shares were sold at an average price of $106.31, for a total value of $127,678.31. Following the sale, the executive vice president now directly owns 25,443 shares in the company, valued at approximately $2,704,845.33. The trade was a 4.51 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Daniel J. Brennan sold 67,333 shares of the firm’s stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $105.24, for a total value of $7,086,124.92. Following the completion of the transaction, the chief financial officer now owns 225,808 shares of the company’s stock, valued at $23,764,033.92. The trade was a 22.97 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 139,630 shares of company stock worth $14,467,616 over the last ninety days. Company insiders own 0.50% of the company’s stock.

Wall Street Analyst Weigh In

BSX has been the subject of a number of research reports. Stifel Nicolaus raised their target price on Boston Scientific from $100.00 to $115.00 and gave the company a “buy” rating in a research note on Thursday, February 6th. UBS Group boosted their target price on shares of Boston Scientific from $105.00 to $130.00 and gave the stock a “buy” rating in a research note on Friday, February 7th. Citigroup increased their price target on shares of Boston Scientific from $107.00 to $122.00 and gave the company a “buy” rating in a research note on Thursday, February 6th. JPMorgan Chase & Co. boosted their price objective on shares of Boston Scientific from $100.00 to $110.00 and gave the stock an “overweight” rating in a research report on Monday, December 16th. Finally, Deutsche Bank Aktiengesellschaft raised Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 target price for the company in a research note on Friday, January 10th. Two research analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $107.39.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.